The estimated Net Worth of Kristin Yarema is at least $1.76 Million dollars as of 11 June 2021. Dr Yarema owns over 34,354 units of Atara Biotherapeutics Inc stock worth over $1,046,079 and over the last 5 years he sold ATRA stock worth over $11,073. In addition, he makes $700,673 as SVP & Chief Commercial Officer at Atara Biotherapeutics Inc.
Dr has made over 2 trades of the Atara Biotherapeutics Inc stock since 2021, according to the Form 4 filled with the SEC. Most recently he bought 34,354 units of ATRA stock worth $500,538 on 11 June 2021.
The largest trade he's ever made was buying 34,354 units of Atara Biotherapeutics Inc stock on 11 June 2021 worth over $500,538. On average, Dr trades about 4,389 units every 3 days since 2020. As of 11 June 2021 he still owns at least 125,882 units of Atara Biotherapeutics Inc stock.
You can see the complete history of Dr Yarema stock trades at the bottom of the page.
Dr. Kristin Yarema Ph.D. is the SVP & Chief Commercial Officer at Atara Biotherapeutics Inc.
As the SVP & Chief Commercial Officer of Atara Biotherapeutics Inc, the total compensation of Dr D at Atara Biotherapeutics Inc is $700,673. There are 4 executives at Atara Biotherapeutics Inc getting paid more, with Pascal Touchon having the highest compensation of $6,637,310.
Dr D is 50, he's been the SVP & Chief Commercial Officer of Atara Biotherapeutics Inc since . There are 11 older and 4 younger executives at Atara Biotherapeutics Inc. The oldest executive at Atara Biotherapeutics Inc is Roy Baynes, 65, who is the Independent Director.
Kristin's mailing address filed with the SEC is C/O POSEIDA THERAPEUTICS, INC., 9390 TOWNE CENTER DRIVE SUITE 200, SAN DIEGO, CA, 92121.
Over the last 10 years, insiders at Atara Biotherapeutics Inc have traded over $58,305,463 worth of Atara Biotherapeutics Inc stock and bought 1,293,860 units worth $5,821,259 . The most active insiders traders include Joel S Marcus, Eric Dobmeier, and Ronald C Jr Renaud. On average, Atara Biotherapeutics Inc executives and independent directors trade stock every 9 days with the average trade being worth of $99,047. The most recent stock trade was executed by Pascal Touchon on 16 August 2024, trading 3,038 units of ATRA stock currently worth $20,142.
we launched atara biotherapeutics in august 2012 to help patients combat cancer, kidney disease and other illnesses. our research is based on groundbreaking discoveries regarding the ability of activin, myostatin and other growth factors to change the course of disease progression. our goal is to help patients such as atara ciechanover, our company’s namesake, who suffered from cancer before passing away in 2012. we aim to empower patients to fight their illnesses with better treatment options. atara biotherapeutics is developing several innovative product candidates, including pinta 745, stm 434 and ata 842, and is collaborating with memorial sloan kettering cancer center (msk) in the development of three t-cell product candidates: epstein-barr virus (ebv)-targeted cytotoxic t lymphocytes (ctls), cytomegalovirus (cmv)-targeted ctls, and wilms tumor 1 (wt1)-targeted ctls. each product candidate is designed to address the underlying mechanisms of disease to treat conditions which have
Atara Biotherapeutics Inc executives and other stock owners filed with the SEC include: